PharVision Advisers’s Credo Technology Group CRDO Stock Holding History

PharVision Advisers’s Portfolio CRDO Stock Details CRDO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,339	Closed	-$337K	–	228
2025 Q4	$337K	Buy	2,339 +843	+56%	+$130K	0.17%	218
2025 Q3	$218K	Buy	+1,496	New	+$183K	0.12%	441
2025 Q1	–	Sell	-3,182	Closed	-$214K	–	317
2024 Q4	$214K	Buy	+3,182	New	+$158K	0.18%	272

Other funds holding CRDO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SIM

SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return

PharVision Advisers's CRDO Position: Q1 2026 in Review

PharVision Advisers sold out of Credo Technology Group (CRDO) in Q1 2026, closing a stake of 2,339 shares — an estimated $337K sold.

PharVision Advisers first reported a position in CRDO in Q4 2024 and held it in 3 quarters. The position peaked at $337K in Q4 2025. 709 funds tracked by Wall St. Rank hold CRDO as of Q1 2026.

PharVision Advisers reported no remaining Credo Technology Group position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 2,339 Credo Technology Group shares in Q1 2026, an estimated $337K.
PharVision Advisers first reported a position in Credo Technology Group in Q4 2024 and held it in 3 quarters.
PharVision Advisers's Credo Technology Group position peaked at $337K in Q4 2025.
709 funds tracked by Wall St. Rank held Credo Technology Group as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.